Compare AU
Compare DRUG vs. VBND
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the Vanguard Global Aggregate Bond Index (Hedged) ETF (VBND). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | VBND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 121 |
Median incremental investment | $967.00 | $1,027.97 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $2,449.34 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | VBND | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | VBND.AX was created on 2017-10-10 by Vanguard. The fund's investment portfolio concentrates primarily on investment grade fixed income. Vanguard Global Aggregate Bond Index (Hedged) ETF seeks to track the return of the Bloomberg Barclays Global Aggregate Float-Adjusted and Scaled Index hedged into Australian dollars before taking into account fees, expenses and tax |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | United States Treasury Note/Bond 4.25 2024-12-31 (0.39 %) United States Treasury Note/Bond 4.5 2024-11-30 (0.37 %) Italy Buoni Poliennali Del Tesoro 3.4 2025-03-28 (0.33 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | |
Management fee | 0.57 % | 0.2 % |
Key Summary
DRUG | VBND | |
|---|---|---|
Issuer | BetaShares | Vanguard |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Bloomberg Barclays Global Aggregate Float Adjusted Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.2 % |
Price | $8.12 | $42.23 |
Size | $191.120 million | $4.291 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 3.65 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 12/10/2017 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | VBND | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 121 |
Median incremental investment | $967.00 | $1,027.97 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,875.72 | $2,449.34 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | VBND | |
|---|---|---|
Pros |
|
|
Cons |
|
|
DRUG | VBND |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Higher management fee | Lower management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |